- risk of
osteoporosis under the
brand name Prolia, and in
November 2010, as
Xgeva for the
prevention of skeleton-related
events in
people with bone metastases...
- and the risk of hip
fractures by 40%. In
November 2010 the FDA
approved Xgeva for the
prevention of
complications of bone
metastases in
patients with...
-
BeiGene acquired the
rights to
commercialize three Amgen pharmaceuticals,
Xgeva, Kyprolis, and Blincyto, as well as 20
others in development, investing...
-
Chugai Pharmaceutical,
Hetero Drugs,
Roche Influenza Oct-1999 Mon-20XX 91
Xgeva Denosumab 197,711 3.24%
Amgen Osteoporosis Nov-2010 Mon-20XX 92
Evista Raloxifene...
- denosumab-bbdz/Jubbonti denosumab/Prolia
March 2024 denosumab-bbdz/Wyost denosumab/
Xgeva March 2024 tocilizumab-aazg/Tyenne tocilizumab/Actemra
April 2024...
- for use in
cancer settings, and in
those indications, it is
branded as
Xgeva. In both
prostate and
breast cancer,
denosumab has been
shown to reduce...
-
intravenous fully human CD38
Multiple myeloma 761036 Link
denosumab Prolia,
Xgeva Amgen 6/1/2010
subcutaneous fully human RANKL Postmenopausal women with...
-
xenytropium bromide (INN)
Xeomin Xepi
Xeplion Xerava Xerese Xermelo Xevudy Xgeva Xhance Xiaflex xibenolol (INN)
xibornol (INN)
Xibrom Xifaxan Xigduo Xigduo...
